Zhong C, Chrzanowska-Wodnicka M, Brown J, Shaub A, Belkin A M, Burridge K
Department of Cell Biology and Anatomy, and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA.
J Cell Biol. 1998 Apr 20;141(2):539-51. doi: 10.1083/jcb.141.2.539.
Many factors influence the assembly of fibronectin into an insoluble fibrillar extracellular matrix. Previous work demonstrated that one component in serum that promotes the assembly of fibronectin is lysophosphatidic acid (Zhang, Q., W.J. Checovich, D.M. Peters, R.M. Albrecht, and D.F. Mosher. 1994. J. Cell Biol. 127:1447-1459). Here we show that C3 transferase, an inhibitor of the low molecular weight GTP-binding protein Rho, blocks the binding of fibronectin and the 70-kD NH2-terminal fibronectin fragment to cells and blocks the assembly of fibronectin into matrix induced by serum or lysophosphatidic acid. Microinjection of recombinant, constitutively active Rho into quiescent Swiss 3T3 cells promotes fibronectin matrix assembly by the injected cells. Investigating the mechanism by which Rho promotes fibronectin polymerization, we have used C3 to determine whether integrin activation is involved. Under conditions where C3 decreases fibronectin assembly we have only detected small changes in the state of integrin activation. However, several inhibitors of cellular contractility, that differ in their mode of action, inhibit cell binding of fibronectin and the 70-kD NH2-terminal fibronectin fragment, decrease fibronectin incorporation into the deoxycholate insoluble matrix, and prevent fibronectin's assembly into fibrils on the cell surface. Because Rho stimulates contractility, these results suggest that Rho-mediated contractility promotes assembly of fibronectin into a fibrillar matrix. One mechanism by which contractility could enhance fibronectin assembly is by tension exposing cryptic self-assembly sites within fibronectin that is being stretched. Exploring this possibility, we have found a monoclonal antibody, L8, that stains fibronectin matrices differentially depending on the state of cell contractility. L8 was previously shown to inhibit fibronectin matrix assembly (Chernousov, M.A., A.I. Faerman, M.G. Frid, O.Y. Printseva, and V.E. Koteliansky. 1987. FEBS (Fed. Eur. Biochem. Soc.) Lett. 217:124-128). When it is used to stain normal cultures that are developing tension, it reveals a matrix indistinguishable from that revealed by polyclonal anti-fibronectin antibodies. However, the staining of fibronectin matrices by L8 is reduced relative to the polyclonal antibody when the contractility of cells is inhibited by C3. We have investigated the consequences of mechanically stretching fibronectin in the absence of cells. Applying a 30-35% stretch to immobilized fibronectin induced binding of soluble fibronectin, 70-kD fibronectin fragment, and L8 monoclonal antibody. Together, these results provide evidence that self-assembly sites within fibronectin are exposed by tension.
许多因素影响纤连蛋白组装成不溶性纤维状细胞外基质。先前的研究表明,血清中促进纤连蛋白组装的一种成分是溶血磷脂酸(Zhang, Q., W.J. Checovich, D.M. Peters, R.M. Albrecht, and D.F. Mosher. 1994. J. Cell Biol. 127:1447 - 1459)。在此我们表明,C3转移酶,一种低分子量GTP结合蛋白Rho的抑制剂,可阻断纤连蛋白和70-kD NH2-末端纤连蛋白片段与细胞的结合,并阻断血清或溶血磷脂酸诱导的纤连蛋白组装成基质。将重组的、组成型活性Rho显微注射到静止的瑞士3T3细胞中可促进注射细胞的纤连蛋白基质组装。在研究Rho促进纤连蛋白聚合的机制时,我们使用C3来确定整合素激活是否参与其中。在C3降低纤连蛋白组装的条件下,我们仅检测到整合素激活状态的微小变化。然而,几种作用方式不同的细胞收缩性抑制剂,可抑制纤连蛋白和70-kD NH2-末端纤连蛋白片段与细胞的结合,减少纤连蛋白掺入脱氧胆酸盐不溶性基质,并阻止纤连蛋白在细胞表面组装成纤维。因为Rho刺激收缩性,这些结果表明Rho介导的收缩性促进纤连蛋白组装成纤维状基质。收缩性增强纤连蛋白组装的一种机制可能是张力暴露了正在被拉伸的纤连蛋白内隐藏的自组装位点。为探究这种可能性,我们发现了一种单克隆抗体L8,它根据细胞收缩状态对纤连蛋白基质进行不同的染色。L8先前已被证明可抑制纤连蛋白基质组装(Chernousov, M.A., A.I. Faerman, M.G. Frid, O.Y. Printseva, and V.E. Koteliansky. 1987. FEBS (Fed. Eur. Biochem. Soc.) Lett. 217:124 - 128)。当用于对正在产生张力的正常培养物进行染色时,它显示出与多克隆抗纤连蛋白抗体所显示的基质无法区分。然而,当细胞收缩性被C3抑制时,相对于多克隆抗体,L8对纤连蛋白基质的染色减少。我们研究了在无细胞情况下机械拉伸纤连蛋白的后果。对固定的纤连蛋白施加30 - 35%的拉伸可诱导可溶性纤连蛋白、70-kD纤连蛋白片段和L8单克隆抗体的结合。总之,这些结果提供了证据表明纤连蛋白内的自组装位点可被张力暴露。